Tech Company Financing Transactions
Helicore Biopharma Funding Round
Helicore Biopharma, based in San Mateo, secured $65 million in funding from OrbiMed, Versant Ventures and Longitude Capital Management.
Transaction Overview
Company Name
Announced On
1/28/2025
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
OrbiMed (Lead Investor) (Rishi Gupta)
Versant Ventures (Lead Investor)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1825 South Grant Street
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Website
Email Address
Overview
Helicore Biopharma, Inc., is a clinic-ready multi-product biopharmaceutical company focused on the discovery and development of novel weight-loss therapeutics. Helicore's lead candidate, HCR-188, is a first-in-class biologic GIP antagonist with a differentiated mechanism of action advancing to the clinic in Q1'25 as a monotherapy and in combination with GLP-1 in induction and maintenance settings. Helicore closed its $65M Series A financing in January 2024 and expects to enter the clinic early 2025.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerrit Klaerner
Browse more venture capital transactions:
Prev: 1/28/2025: Token Security venture capital transaction
Next: 1/28/2025: iPronics venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to record funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs